LTx has the shortest survival of all solid organ transplants. The complex and time-demanding diagnostics of allograft dysfunction are a significant reason for this. The current study aims overarchingly to improve survival after lung transplantation (LTx) through precise and fast diagnostics. The specific aim is to develop direct-to-clinical implementation biomarkers for the most important aspects of long-term survival after LTx. An in-house-developed PCR-based cell-free-DNA methodology (cf-DNA) will be used for allograft damage and combined with specific other biomarkers to identify damage type. The current clinical golden standard for damage identification will be performed at every sampling instance. The research will be a single-centre prospective observational cohort study. The control samples at all time points will consist of the samples without allograft damage. Blood will be drawn at fixed time points and clinical events. All analyses will be performed at a separate lab, blinded to the patient's status. .
Study Type
OBSERVATIONAL
Enrollment
146
Blood samples taker per protocol, analyses performed by a lab blinded to the status of the respective patients
Sahlgrenska University hospital
Gothenburg, Västra Götaland County, Sweden
RECRUITINGDamage distinction
Null hypothesis: Levels of Cf-DNA is not different at samples taken with allograft damage and no allograft damage.
Time frame: One month, three months, one year, three years, five years
Damage detection Limit
If the null hypothesis is disproven, measure optimal cut off for distincition beteween samples indicating damage and not indicating damage. Also distinction between different types of damage, finally if distinction is attainable trhough association wit other known biomarkers.
Time frame: One month, three months, one year, three years, five years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.